SEC Form 4 · accession 0001144204-15-045575
IMMUNE PHARMACEUTICALS INC · IMNP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Gedeon Teper
Officer — CEO · Director · 10% Owner
Period of report
Jul 8, 2015
Accepted (ET)
Jul 31, 2015 · 6:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001208261
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 8, 2015 | C | 8,905 | $1.51 | A | 4,453,636 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series C 8% Convertible Preferred StockF1,F2,F3 | $1.51 | Jul 8, 2015 | C | 12 | D | — | — | Common Stock | 8,905 | 0 | D |
Explanation of responses
- F1The Series C 8% Convertible Preferred Stock is convertible upon issuance.
- F2The Series C 8% Convertible Preferred Stock does not have an expiration date.
- F3Includes 841 shares of Common Stock for accrued dividends.